Last 20 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.34 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.79 | 7.07 | 4.96 | 2.82 | 2.23 | 0.65 | 0.71 | 5.94 | 6.57 | 4.10 | 5.12 | 5.77 | 4.28 | — | — | — | — | — | — | — | — |
| — | +990.6% | +601.9% | -52.6% | -66.1% | -84.2% | -86.2% | +3.0% | +53.7% | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -121.2% | -74.8% | -61.3% | -50.4% | -36.0% | -25.6% | -26.4% | -19.4% | -20.7% | -14.6% | -12.0% | -22.1% | -10.3% | — | -9.7% | — | — | — | — | — | — |
| — | -191.7% | -132.2% | -160.3% | -74.3% | -76.0% | -119.4% | +12.6% | -99.8% | — | -23.4% | — | — | — | — | — | — | — | — | — | — | |
| ROA | -93.3% | -30.9% | -31.0% | -32.2% | -28.3% | -21.9% | -23.7% | -17.6% | -19.2% | -13.7% | -11.4% | -20.9% | -11.7% | -10.3% | -8.7% | -7.1% | -8.1% | -10.6% | -6.1% | -54.8% | -10.1% |
| — | -40.7% | -30.8% | -83.4% | -47.4% | -59.8% | -108.8% | +15.9% | -63.5% | -34.0% | -30.4% | -193.1% | -44.0% | +3.3% | -42.3% | +87.0% | +19.4% | — | — | — | — | |
| ROIC | -527.4% | — | — | — | -105.6% | -44.8% | -42.7% | -48.5% | -40.8% | -19.9% | -26.0% | -36.3% | — | — | — | — | — | — | — | — | — |
| — | — | — | — | -159.1% | -125.0% | -64.1% | -33.5% | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.11 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | — | 0.02 | — | — | — | — | — | — |
| — | -93.0% | +41.2% | -28.9% | -53.8% | +1053.7% | -60.6% | -42.1% | -28.6% | — | -50.1% | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.87 | 4.50 | 5.09 | 5.87 | 6.85 | 10.54 | 8.98 | 10.51 | 10.98 | 17.22 | 17.99 | 19.05 | 18.05 | 12.90 | 16.53 | 16.37 | 14.89 | 20.24 | 17.85 | 21.15 | 20.69 |
| — | -57.3% | -43.3% | -44.1% | -37.6% | -38.8% | -50.1% | -44.8% | -39.2% | +33.5% | +8.9% | +16.3% | +21.2% | -36.3% | -7.4% | -22.6% | -28.0% | — | — | — | — | |
| Quick Ratio | 5.87 | 4.50 | 5.09 | 5.87 | 6.85 | 10.54 | 8.98 | 10.51 | 10.98 | 17.22 | 17.99 | 19.05 | 18.05 | 12.90 | 16.53 | 16.37 | 14.89 | 20.24 | 17.85 | 21.15 | 20.69 |
| — | -57.3% | -43.3% | -44.1% | -37.6% | -38.8% | -50.1% | -44.8% | -39.2% | +33.5% | +8.9% | +16.3% | +21.2% | -36.3% | -7.4% | -22.6% | -28.0% | — | — | — | — | |
| Interest Coverage | -72.56 | -23.18 | -27.82 | -28.20 | -74.98 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 20 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NMRA stock.
Neumora Therapeutics, Inc. Common Stock's current P/E is -0.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Neumora Therapeutics, Inc. Common Stock's business trajectory between earnings reports.